Iferanserin (INN; VEN-309) is a drug which acts as a selective 5-HT2A receptor antagonist.[1] It is under development as an intra-rectal formulation for the treatment of hemorrhoid disease, and as of February 2012, is in phase IIb clinical trials.[1]

References

  1. ^ a b Herold A, Dietrich J, Aitchison R (February 2012). "Intra-anal Iferanserin 10 mg BID for hemorrhoid disease: a prospective, randomized, double-blind, placebo-controlled trial". Clinical Therapeutics. 34 (2): 329–40. doi:10.1016/j.clinthera.2011.12.012. PMID 22244049.


Allikas: https://en.wikipedia.org/wiki/Iferanserin
No tags for this post.